Short- or longer-term relugolix achieves sustained castration in patients with localized and advanced prostate cancer. Short- or longer-term relugolix achieves sustained castration in patients with localized and advanced prostate cancer.
Besides enabling more efficient workflow, the technology can improve diagnostic accuracy and treatment. Artificial intelligence can be particularly useful in analyzing large numbers of medical images.
No new safety concerns were reported in patients who received relugolix with radiation therapy. A study probed the efficacy and safety of the oral GnRH antagonist relugolix with radiation therapy for prostate cancer.
Investigators report promising results from a phase 2 trial of an investigational aldosterone synthase inhibitor. BI 690517, a novel investigational aldosterone synthase inhibitor, may improve clinicians’ ability to slow progression of chronic kidney disease.